重庆太极实业(集团)股份有限公司2025 年半年度报告摘要 公司代码：600129 公司简称：太极集团 重庆太极实业(集团)股份有限公司 第一节 重要提示 展规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司2025年半年度不进行利润分配，也不进行资本公积金转增股本。 第二节 公司基本情况 公司股票简况 | 股票种类 | 股票上市交易所 | 股票简称 | 股票代码 变更前 | | --- | --- | --- | --- | | 股票简称 | | | | | A股 | 上海证券交易所 | 太极集团 | 600129 - | | 联系人和联系方式 | | 董事会秘书 | 证券事务代表 | | 姓名 | 蒋茜 | 徐旺 | | | 电话 | 023-89886129 | 023-89886129 | | | 办公地址 | | 重庆市渝北区恒山东路18号 | 重庆市渝北区恒山东路 | | 18号 | | | | | 电子信箱 | tjzq@taiji.com | tjzq@taiji.com | | | ...

证券代码：600129 证券简称：太极集团 公告编号：2025-062 重庆太极实业（集团）股份有限公司 第十届董事会第三十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第三十一次会议于 2025 年 8 月 11 日以邮件方式发出书面通知， 于 2025 年 8 月 20 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 13 人，实到董事 13 人，公司高级管理人员 列席了会议。本次会议的召集、召开程序符合《公司法》和《公司章 程》的有关规定，会议合法有效。会议审议并通过了如下议案： 一、公司《2025 年半年度报告及半年度报告摘要》（具体内容 详见公司在上海证券交易所网站（www.sse.com.cn）披露的《2025 半年度报告及半年度报告摘要》） 委员会第十八次会议审议通过。 重庆太极实业（集团）股份有限公司 表决情况：同意 13 票，弃权 0 票，回避 0 票，反对 0 票；表决 结果：通过。 二、关于对国药集 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-064 重庆太极实业（集团）股份有限公司 关于公开挂牌出售闲置房产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 一、交易概述 （一）交易基本情况 为盘活闲置资产，提高资产运营效率，提高资产的流动性，公司 拟将名下位于成都市成华区建设路 52 号房产以公开挂牌的形式在产 权交易所进行挂牌转让，本次挂牌转让价格以评估值 3,913.60 万元 为依据，首次公开挂牌转让价格为 3,913.60 万元，最终交易金额以 实际成交价格为准。 本次交易将通过公开挂牌的方式转让，交易对方和最终交易价格 存在不确定性，最终转让能否成功尚存在不确定性，公司将根据交易 进展情况及时履行信息披露义务。 根据《上海证券交易所股票上市规则》及《公司章程》的规定， 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 重庆太极实业（集团）股份有限公司（以下简称：公司）拟将公 司名下位于成都市成华区建设路 52 号房产以公开挂牌的方式在产权 交易所出售 ...

Core Viewpoint - The company, Chongqing Taiji Industrial (Group) Co., Ltd., reported a significant decline in its main business revenue and profit margins for the first half of 2025, indicating challenges in various segments of its operations [1][2]. Summary by Category 1. Main Business Revenue and Costs - The total main business revenue for the first half of 2025 was 559,588.74 million RMB, a decrease of 27.61% compared to the previous year [1][2]. - The main business cost was 405,416.86 million RMB, which saw a slight decrease of 1.48% [1][2]. - The overall gross margin was reported at 27.55%, down by 19.21 percentage points year-on-year [1][2]. 2. Segment Performance - **Pharmaceutical Industry**: Revenue was 284,234.75 million RMB, with a gross margin of 42.44%, down 20.46% year-on-year. The cost was 507,878.28 million RMB, reflecting a significant decline in profitability [1]. - **Pharmaceutical Commerce**: Revenue reached 337,213.55 million RMB, with a gross margin of 8.45%, down 0.33%. The cost was 374,145.79 million RMB, indicating a decrease of 9.87% [1]. - **Traditional Chinese Medicine Resources**: Revenue was 49,274.89 million RMB, with a gross margin of 8.51%, showing a slight increase of 0.74%. The cost was 49,005.69 million RMB [1]. - **Health and International Services**: Revenue dropped to 9,514.72 million RMB, with a gross margin of 8.47%, down 0.71%. The cost was 26,542.95 million RMB, reflecting a 64.15% decrease [1]. - **Other Services**: Revenue was 68.42 million RMB, with a gross margin of 66.63%, down 16.17%. The cost was 189.81 million RMB, a decrease of 63.95% [1]. 3. Regional Performance - **Southwest Region**: Revenue was 379,714.39 million RMB, with a gross margin of 20.73%, down 8.58% [2]. - **East China**: Revenue was 87,061.98 million RMB, with a gross margin of 40.94%, down 46.85% [2]. - **South China**: Revenue was 28,509.92 million RMB, with a gross margin of 38.09%, down 56.80% [2]. - **North China**: Revenue was 24,147.85 million RMB, with a gross margin of 56.99%, down 57.66% [2]. - **Central China**: Revenue was 19,341.36 million RMB, with a gross margin of 37.22%, down 47.85% [2]. - **Northwest Region**: Revenue was 11,126.22 million RMB, with a gross margin of 38.00%, down 45.33% [2]. - **Northeast Region**: Revenue was 9,317.72 million RMB, with a gross margin of 38.49%, down 27.12% [2]. - **Overseas**: Revenue was 369.30 million RMB, with a gross margin of 49.63%, down 34.18% [2].

Core Viewpoint - The report evaluates the ongoing risks associated with the financial transactions between Chongqing Taiji Industrial (Group) Co., Ltd. and China National Pharmaceutical Group Financial Co., Ltd., confirming the latter's compliance with regulatory requirements and sound risk management practices [1][9]. Group 1: Basic Information of China National Pharmaceutical Group Financial Co., Ltd. - Established in February 2012, the company is a non-bank financial institution approved by the former China Banking Regulatory Commission [1]. - The registered capital is RMB 2.2 billion, with 100% ownership by its shareholders [1]. - The business scope includes accepting deposits, providing loans, bill discounting, and various financial advisory services [1]. Group 2: Internal Control and Risk Management - The company has established a comprehensive internal control system, including a governance structure with a board of directors and various committees [2][3]. - A risk management department and an internal audit department are in place to oversee business activities and ensure compliance with established procedures [2][3]. - The internal control system includes specific guidelines for settlement and credit operations, ensuring effective risk management [3][4]. Group 3: Operational and Financial Performance - As of June 30, 2025, the total assets of the company amounted to RMB 41.867 billion, with a loan balance of RMB 17.319 billion and an operating income of RMB 372 million [6][7]. - The company has maintained stable operations and steady growth across its various business lines since its inception [6][7]. Group 4: Regulatory Compliance - As of June 30, 2025, all regulatory indicators of the company met the required standards, including a loan-to-deposit ratio of 43.41% [8]. - The company has not encountered any significant deficiencies in its risk control systems related to financial reporting and management [7][9]. Group 5: Risk Assessment Conclusion - The company possesses valid financial licenses and has adhered to the regulations set forth in the Enterprise Group Financial Company Management Measures [9]. - The risk management practices of the company are deemed effective, with no major flaws identified in its operations [9].

三、对公司的影响及风险提示 （一）截至本公告披露日，上述银行账户本次被申请冻结金额合 计 6,292.12 万元，占公司最近一期经审计净资产的 1.73%；占公司 最近一期经审计货币资金的 7.75%，除上述披露的银行账户冻结情形 外，公司尚有其他银行账户可正常使用，上述银行账户被冻结暂未对 重庆太极实业（集团）股份有限公司 公司的正常运行、经营管理造成重大不利影响。 （二）鉴于本次银行账户部分资金被冻结所涉及西藏慧业案件 尚未正式诉讼、杭州悦明案件尚未判决，对公司本期及期后损益的影 响具有不确定性，实际影响以最终判决结果为准。 证券代码：600129 证券简称：太极集团 公告编号：2025-067 重庆太极实业（集团）股份有限公司 关于公司及子公司部分银行账户被冻结的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、账户被冻结情况 重庆太极实业（集团）股份有限公司（以下简称：公司）财务人 员查询银行账户时获悉公司及子公司西南药业股份有限公司（以下简 称：西南药业）部分银行账户被冻结，具体情况如下： 账户名称 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-065 重庆太极实业（集团）股份有限公司 关于召开 2025 年半年度业绩说明会的 公告 ??会议召开时间：2025 年 9 月 2 日（星期二）14:00-15:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 2025 年 8 月 26 日（星期二）至 9 月 1 日（星期一） 公司邮箱 tjzq@taiji.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 重庆太极实业(集团)股份有限公司（以下简称"公司" ）已于 2025 年 8 月 22 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、 财务状况， 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with the total repurchase amount ranging from 80 million to 120 million yuan, aimed at canceling and reducing its registered capital [1][3][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between 80 million yuan and 120 million yuan [1][3]. - The funding sources for the repurchase will be the company's own funds or funds raised [1][7]. - The maximum repurchase price is capped at 28.03 yuan per share, which is 130% of the average trading price over the previous 30 trading days [1][6]. - The shares repurchased will be used entirely for cancellation and reduction of registered capital [1][3][4]. Implementation Procedures - The repurchase plan was approved in meetings held on July 16 and August 6, 2025 [2]. - The implementation period for the repurchase is set for 12 months from the date of shareholder approval [3][4]. - The company has notified creditors as required by law, and consent from creditors is necessary for the plan to proceed [2][11]. Financial Impact - The total share capital of the company is 556,890,744 shares, with the repurchase potentially reducing the total shares by approximately 4,281,127 shares, representing 0.77% of the total [5][7]. - The estimated financial impact of the repurchase, based on the upper limit of 120 million yuan, is minimal, accounting for 0.85% of total assets, 1.79% of current assets, and 3.44% of net assets attributable to shareholders [8]. Shareholder Considerations - The company has confirmed that there are no plans for major shareholders or executives to sell shares in the next three to six months [10][11]. - The repurchase will not affect the company's operational stability or its listing status [8][13]. Regulatory Compliance - The company has established a dedicated securities account for the repurchase, ensuring compliance with relevant regulations [13]. - The management is authorized to handle all necessary procedures related to the repurchase, including adjustments to the plan as needed [11][12].

[注 1] 呼吸系统用药的营业收入较上年同期减少 44.69%，主要系本报告 期急支糖浆、鼻窦炎口服液、散列通等销售额减少所致。 证券代码：600129 证券简称：太极集团 公告编号：2025-063 重庆太极实业（集团）股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》 之《第六号—医药制造》的相关规定，现将公司 2025 年半年度主要经营数据 披露如下： | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 主营业务收入 2025 年 | 2024 年 | 增长率% | 主营业务成本 2025 年 | 2024 年 | 增长率% | 毛利率% 2025 年 | 2024 年 | 同比增长 百分点 | | | 1-6 月 | 1-6 月 | | 1-6 月 | ...

重要内容提示： 会议召开时间：2025 年 9 月 2 日（星期二）14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 26 日（星期二）至 9 月 1 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 tjzq@taiji.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 证券代码：600129 证券简称：太极集团 公告编号：2025-065 重庆太极实业（集团）股份有限公司 关于召开 2025 年半年度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 三、参加人员 董事长：俞敏先生 总经理：于宗斌先生 重庆太极实业(集团)股份有限公司（以下简称"公司"）已于 2025 年 8 月 22 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财 ...